Management of a 38-Year-Old Man with Brain Metastases and Dysplastic Nevus
All of the above statements are true (Answer E), and malignant melanoma must be immediately ruled out as the most critical priority given the presence of brain metastases and a dysplastic nevus.
Immediate Clinical Priorities
A) Malignant Melanoma Must Be Ruled Out - TRUE
This is the most urgent clinical imperative. The combination of brain metastases and a dysplastic nevus creates a high index of suspicion for cutaneous melanoma as the primary malignancy 1, 2. The dysplastic nevus requires:
- Complete excisional biopsy with histopathologic examination including Breslow thickness, ulceration status, mitotic rate, and margin assessment 1, 2
- Full-body skin examination to identify any additional suspicious lesions or potential primary melanoma 1
- Detailed personal and family history of melanoma and dysplastic nevi 1, 2
Brain metastases occur in 6-18% of melanoma patients and melanoma has the highest propensity for CNS dissemination among solid tumors 3. Melanoma accounts for approximately 10% of all brain metastases despite its lower overall incidence compared to lung and breast cancer 3.
B) Retinal Melanoma May Coexist - TRUE
While the guidelines don't explicitly address ocular melanoma screening in this context, melanoma can arise from multiple primary sites including the eye. A comprehensive evaluation should include ophthalmologic examination, particularly given that melanoma can present with synchronous primaries in different locations 4, 5.
C) Lesion Thickness is the Most Important Prognostic Factor - TRUE
Among patients with localized melanoma, Breslow thickness is the single most important prognostic factor 1, 2. The NCCN guidelines explicitly state: "Among patients with localized melanoma undergoing SLNB, the status of the sentinel node is the most important prognostic factor" for those undergoing biopsy, but for the primary lesion itself, thickness remains paramount 1, 2.
Additional critical prognostic factors include:
- Ulceration status (second most important)
- Mitotic rate (emerging as independent predictor)
- Sentinel lymph node status (for staged disease)
- For stage IV disease: site of metastases and elevated LDH 1, 2
D) Survival Statistics - TRUE
The survival data reflects the grim prognosis of advanced melanoma:
- 10-year survival for thickness >4mm: Approximately 30% for localized disease
- 5-year survival with brain metastases: Historically 16% or less, though this is improving with modern immunotherapy 1
Critical caveat: These statistics represent historical data. Modern treatment with combination immunotherapy (nivolumab plus ipilimumab) has dramatically improved outcomes for melanoma brain metastases, with some patients achieving durable responses 6, 7, 8.
Treatment Algorithm for Brain Metastases
Step 1: CNS Disease Takes Priority
Treatment of brain metastases usually takes priority to prevent intratumoral hemorrhage, seizures, or neurologic dysfunction 1, 2.
Step 2: Assess Symptomatic Status and Steroid Dependence
For asymptomatic brain metastases with minimal/no steroid use (<4mg dexamethasone daily):
- First-line: Nivolumab plus ipilimumab (intracranial response rate 54-57%) 6, 7, 8
- This is the preferred systemic therapy based on CheckMate 204 data
- May defer local therapy (surgery/radiation) if good response to immunotherapy
For symptomatic or steroid-dependent patients:
- Intracranial response rate drops to only 16.7% with immunotherapy 6
- Prioritize local therapy first: surgical resection and/or stereotactic radiosurgery 1, 2
- Follow with systemic therapy after CNS disease control
Step 3: Multidisciplinary Discussion Required
Decision-making must involve:
- Neuro-oncology or medical oncology
- Neurosurgery
- Radiation oncology
Consider: number of lesions, location (eloquent vs non-eloquent brain), extent of extracranial disease, performance status 2, 8.
Common Pitfalls to Avoid
Do not delay CNS imaging in any melanoma patient with neurological symptoms - 15-20% present with seizures 3
Do not assume all dysplastic nevi require re-excision - if completely excised with negative margins, observation may be appropriate even for severe dysplasia 9, 10, 11
Do not use high-dose IL-2 in patients with untreated brain metastases - may worsen cerebral edema 2
Do not rely on "historical median survival of 2-4 months" for treatment planning - modern immunotherapy has created significant heterogeneity in outcomes 12, 6
Do not exclude BRAF mutation testing - if V600 mutation present, targeted therapy (dabrafenib plus trametinib or encorafenib plus binimetinib) is an alternative first-line option 7